The Innovation and Business team works with Crick researchers, university partners and the wider biosciences ecosystem to create pathways that apply Crick science and expertise to benefit society, human health and economic growth. 

Work with us

Get in touch with the Crick's Innovation and Business team to find out more about how you can work with us. 

Email us

The Innovation and Business team

Scientific translation

  • Translation expertise and funding
  • Industry partnerships
  • Entrepreneurship

KQ Labs

Business development

  • Intellectual property and patents
  • Licensing
  • Spin-out companies

Business opportunities

  • Scientific services
  • Digital data and technology
  • Consulting

Ecosystem development

Innovation and business operations

  • Processes and policies
  • Resourcing
  • Reporting and metrics

Translational Governance

Translation Science Advisory Committee

Our Translation Science Advisory Committee of senior Crick scientists and technology leaders offers expert insight and support at the Crick by:

  • Reviewing the scientific quality of translation project applications
  • Advising on funding for i2i translational projects proposed by Crick researchers
  • Making recommendations for subsequent review by the Translation Advisory Board for i2d translational projects proposed by Crick researchers

Chair:

  • Peter Parker, Emeritus Group Leader and Translation Adviser

Observers:

  • Stephen Mayhew, Crick Chief Business Officer

Core members:

  • Dave Allen, Director of Translation
  • Simon Boulton, Principal Group Leader and Crick Translation and Commercial Ambassador
  • Richard Treisman, Director of Research
  • Elisabete Silva, Director of Scientific Platforms
  • Adrian Hayday, Principal Group Leader
  • Katrin Rittinger, Principal Group Leader
  • Andreas Schaefer, Principal Group Leader
  • James Turner, Principal Group Leader
  • Carola Vinuesa, Principal Group Leader
  • Neil McDonald, Principal Group Leader
  • Charlie McTernan, Group Leader
  • Edward McGowan, Head of Translational Science 

Translation Advisory Board

 

Our Translation Advisory Board of industry and academic scientists, funders and entrepreneurs, offers expert insight and support translation at the Crick by:

  • Advising on funding for translational projects proposed by researchers at the Crick.
  • Reviewing project plans for technologies ready to be transferred to industry or clinical partners.
  • Making recommendations for improving delivery of the Crick’s translation strategy.
  • Encouraging the translational research culture at the Crick by bringing ideas, expertise and experience.

Membership

Chairs:

  • David Roblin, Crick Senior Translation Scientific Fellow
  • Peter Parker, Crick Emeritus Group Leader and Translation Adviser

Crick members:

  • Peter Ratcliffe, Crick Clinical Director
  • Simon Boulton, Crick Principal Group Leader and Translation and Commercial Ambassador
  • Stephen Mayhew, Crick Chief Business Officer
  • Dave Allen, Crick Director of Translation
  • Ed McGowan, Crick Head of Translational Science 

Observers:

  • Tony Hickson, Chief Business Officer, CRUK
  • Morag Foreman, Head of Discovery Researchers, Wellcome Trust
  • Barbara Domayne-Hayman, Crick Entrepreneur in Residence
  • Donna Hackett, Crick Head of Business Development
  • Paul Mercer, Crick Head of Industry Partnerships

External members:

  • Jeanne Bolger, Independent Consultant and Board member
  • Gillian Burgess, Executive Vice President, Head of Research, Grünenthal
  • Robin Carr, Chief Technology Officer, Myricx Bio
  • Alicia El-Haj, Interdisciplinary Chair of Cell Engineering and Director of the Institute of Translational Medicine, University of Birmingham
  • Zoe Johnson, Head of Gubra Ventures
  • Manos Perros, Freelance Pharma and Biotech Executive
  • John Pritchard, Independent Consultant
  • David Powell, President of Drug Discovery, Relation Therapeutics
  • Lorenz Mayr, Independent Consultant
  • Louise Modis, Chief Scientific Officer, Amphista Therapeutics
  • Chris Molloy, Chief Executive Officer, Medicines Discovery Catapult 
  • Natalie Mount, Venture Partner at Abingworth
  • George Orphanides, Chief Scientific Officer, LifeArc
  • Mike Romanos, Associate Dean of Enterprise, Imperial College
  • John Shields, Director, JGS Biopharma
  • Roberto Solari, Venture Partner, Brandon Capital
  • Jan Wolber, Head of Technology Leader group, GE Healthcare